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Abstract: Osteoporosis is considered a major public health problem worldwide. In order to develop
effective physical exercise protocols for the prevention of osteoporosis and ensure skeletal integrity,
the intensity of the exercise must be quantified objectively and accurately. This study aimed to assess
the validity of a wearable accelerometer-based activity monitor for use in osteoporosis prevention
programs. Eighteen premenopausal women completed an exercise protocol consisting of five
countermovement jumps followed by four treadmill bouts at different speeds. Participants carried
two pairs of accelerometers (Muvone® and ActiGraph GT3X+) located on the wrist and hip.
Three types of analysis were performed: (1) association between measurements from both devices; (2)
level of similarity in group estimates; and (3) evaluation of measurement bias. High to almost perfect
correlations between the peak acceleration measured by both devices were found in all protocol tests
(r = 0.607–0.975, p < 0.001). Differences in group estimates were non-significant and measurement
bias between devices was below 6%. In conclusion, the validity of Muvone® to quantify acceleration
has been tested at both the wrist and hip and could be used to assess mechanical loading during
physical activities for the implementation of population-wide osteoporosis prevention programs.
Keywords: osteoporosis; prevention; exercise; accelerometer; wearable
1. Introduction
Osteoporosis is a skeletal disease characterized by reduced bone mass and disruption of bone
architecture, leading to increased bone fragility and fracture risk [1]. This condition is highly prevalent
worldwide. It is estimated that osteoporosis affects 27.5 million adults in the European Union [2] and
10.2 million people in the United States [3]. Further, it is expected that one in three women and one in
five men over the age of 50 years will suffer a fracture due to osteoporosis [4]. These figures exhibit an
important economic burden. In Europe, the costs associated with osteoporotic fractures hospitalization
and aftercare are estimated at €37 billion annually [2]. In Spain the number of individuals with
osteoporosis is estimated at 2.5 million, generating a cost for the health care system of €3.5 billion
per year [5]. Moreover, these costs are expected to increase twofold by 2050 based on the expected
demographic changes [6]. This large burden on health systems demonstrates that osteoporosis is
a major public health concern worldwide. It is therefore clearly of interest that effective osteoporosis
prevention programs are developed.
Sustainability 2020, 12, 2187; doi:10.3390/su12062187 www.mdpi.com/journal/sustainability
Sustainability 2020, 12, 2187 2 of 11
Among the strategies that may help in preventing osteoporosis, regular exercise is recommended
for a variety of health and fitness reasons. Evidence shows that different types of activities (e.g., aerobic
exercise and strength training) have an effect on the bone mineral density (maintenance and stimulation)
in both pre- and post-menopausal women [7]. Bones are living tissues and have the capacity to adapt
to physical activity by increasing their size, shape or density in order to better resist biomechanical
demands [8]. Specifically, exercise increases bone mineral density (BMD), bone mass and bone strength
by stimulating osteogenic pathways and the activities of osteoblasts and osteocytes, as well as by
inhibiting osteoclastogenesis and bone resorption [9]. For bone mass to increase, bone tissue must
be stimulated with loads exceeding a certain threshold, as the osteogenic response depends on the
magnitude of mechanical forces applied [10]. In this regard, previous research [11] has highlighted
the importance of reaching accelerations above 3.9 g during physical activity to elicit positive bone
adaptations. Therefore, it is suggested that in order to develop effective protocols for osteoporosis
prevention and to ensure skeletal integrity, exercise intensity must be objectively quantified and
monitored (i.e., bone-loading forces).
To that end, new technologies such as accelerometry are increasingly being used to monitor exercise
and assess mechanical loading in physical activities [10]. An accelerometer is an electromechanical
device that converts mechanical motion into an electrical signal [12]. Therefore, these devices can
provide objective measurements of movement (i.e., physical activity) and could assist in implementing
effective osteoporosis prevention programs. Advances in commercially available accelerometry-based
activity monitors represent an opportunity for a wider population to assess the intensity of different
types of activities. Nevertheless, the cost of reliable accelerometers is still high and interpretation of
the resulting data by the user remains a challenge [13]. Moreover, there is a paucity of data regarding
the validity of wearable accelerometer-based activity monitors aimed at preventing osteoporosis [10].
Consequently, the aim of this study was to determine the validity of a wearable accelerometer-based
activity monitor in order to assess its suitability for the implementation of population-wide osteoporosis
prevention programs.
2. Materials and Methods
2.1. Participants
Eighteen healthy premenopausal women (mean (SD) age 44 (5) years; mass 63 (9) kg; stature
165 (7) cm) from Seville (Spain) and surrounding areas volunteered to participate in this study.
Participants were provided with detailed information about the study and confirmed their ability to
participate in the exercise protocol. This study was approved by the Andalusian Biomedical Research
Ethics Committee and all participants provided written informed consent.
2.2. Procedures
This study aimed at assessing the validity of a wearable accelerometer-based activity monitor
(Muvone®, Secmotic, Seville, Spain) that integrates the BMX055 chip (Bosch Sensortec, Germany),
which is a triaxial 12-bit acceleration sensor designed for modern mobile consumer electronic devices.
The Muvone® was compared with an ActiGraph GT3X+ (ActiGraph LLC, Pensacola, FL) during
different exercise protocols described below. ActiGraph activity monitors were used as reference
monitors, as they are widely used in physical activity research [14] and their reliability to measure
acceleration accurately has been previously reported [15].
The GT3X+ and the Muvone® are portable lightweight devices (GT3X+: 27 g, 3.8 cm × 3.7 cm ×
1.8 cm; Muvone®: 9 g, 3.2 cm × 3.2 cm × 1.1 cm). Participants wore a securely adjusted belt containing
a GT3X+ and a Muvone® positioned over the non-dominant hip (iliac crest). a securely adjusted
wristband containing a GT3X+ and a Muvone® was attached at the non-dominant wrist (upper wrist
crease). Thus, two pairs of GT3X+ and Muvone® units were used and taped together to ensure axis
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alignment. Figure 1 depicts the placement of the accelerometers. At the end of each exercise bout,
researchers ensured that both belt and wristband continued to be adequately fitted.Sustainability 2020, 12, x FOR PEER REVIEW 3 of 11 
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Figure 1. Muvone® and GT3X+ accelerometers adjacent and taped together, positioned over the non-
dominant hip and wrist. 
Prior to engaging in the exercise protocol, participants were instructed on how to safely use the 
treadmill and were familiarized with the study tests. Upon placement of the accelerometers, 
participants completed a standardized exercise protocol during a laboratory-based activity session. 
The exercise protocol was comprised of five countermovement jumps (CMJ) with a 30 s rest between 
each jump. Jump height was measured with a light barrier system (OptoGait, Microgate, Bolzano, 
Italy). Participants then performed four treadmill activities (HP-Cosmos®, Traunstein, Germany), 
walking/running at 4.8, 6.4, 9.7 and 12 km·h-1, replicating the protocol previously described by Sasaki, 
John and Freedson [14]. The duration of each treadmill bout was 2 min with a 1 min rest between 
each condition. Participants stood still during rest intervals and completed every exercise protocol in 
a randomized order. To assess the spatiotemporal gait parameters during the protocol, a floor-based 
photocell system (OptoGait, Microgate, Bolzano, Italy) was used. 
2.3. Data Analysis 
In order to test the validity of Muvone® in comparison to the GT3X+, both devices were 
initialized to collect raw acceleration in three individual orthogonal planes (vertical (VT), antero-
posterior (AP) and medio-lateral (ML)), at a sample rate of 40 Hz. The resultant analog signals were 
digitized by a 12-bit analog-to-digital converter. The validity of Muvone® has been tested using raw 
acceleration data as it may capture the sporadic nature of daily life physical activity more accurately 
than epoch data [15]. The GT3X+ monitors were updated with firmware version 3.2.1. Participants 
having data from both activity monitors at each location (hip and wrist) were included in the inter-
monitor statistical analyses. From the raw acceleration data recorded by each device (in g units), the 
tri-axial vector magnitude (VM) was computed as VM = sqrt(VT2 + AP2 + ML2) [14]. Then, the peak 
acceleration value registered at each second in the VM was extracted to build the peak acceleration 
vector [16]. 
Three types of analyses were performed to test the validity of the Muvone®, following the 
recommendations provided by Welk et al. [17]. Analysis 1: Association between peak acceleration 
measurements from both devices, evidenced by Pearson correlation coefficients (r) with the following 
qualitative interpretation: negligible (< 0.1), small (0.1–0.29), moderate (0.3–0.49), high (0.5–0.69), very 
high (0.7–0.89) or almost perfect (≥ 0.9) [18]. Analysis 2: Level of similarity in group estimates, 
Figure 1. Muvone® and GT3X+ accelerometers adjacent and taped together, positioned over the
non-dominant hip and wrist.
Prior to engaging in the exercise protocol, participants were instructed on how to safely use
the treadmill and were familiarized with the study tests. Upon placement of the accelerometers,
participants completed a standardized exercise protocol during a laboratory-based activity session.
The exercise protocol was comprised of five countermovement jumps (CMJ) with a 30 s rest between
each jump. Jump height was measured with a light barrier system (OptoGait, Microgate, Bolzano,
Italy). Participants then performed four treadmill activities (HP-Cosmos®, Traunstein, Germany),
walking/running at 4.8, 6.4, 9.7 and 12 km·h−1, replicating the protocol previously described by Sasaki,
John and Freedson [14]. The duration of each treadmill bout was 2 min with a 1 min rest between
each condition. Participants stood still during rest intervals and completed every exercise protocol in
a randomized order. To assess the spatiotemporal gait parameters during the protocol, a floor-based
photocell system (OptoGait, Microgate, Bolzano, Italy) was used.
2.3. Data Analysis
In order to test the validity of Muvone® in comparison to the GT3X+, both devices were initialized
to collect raw acceleration in three individual orthogonal planes (vertical (VT), antero-posterior (AP)
and medio-lateral (ML)), at a sample rate of 40 Hz. The resultant analog signals were digitized by
a 12-bit analog-to-digital converter. The validity of Muvone® has been tested using raw acceleration
data as it may capture the sporadic nature of daily life physical activity more accurately than epoch
data [15]. The GT3X+ monitors were updated with firmware version 3.2.1. Participants having data
from both activity monitors at each location (hip and wrist) were included in the inter-monitor statistical
analyses. From the raw acceleration data recorded by each device (in g units), the tri-axial vector
magnitude (VM) was computed as VM = sqrt(VT2 + AP2 + ML2) [14]. Then, the peak acceleration
value registered at each second in the VM was extracted to build the peak acceleration vector [16].
Three types of analyses were performed to test the validity of the Muvone®, following the
recommendations provided by Welk et al. [17]. Analysis 1: Association between peak acceleration
measurements from both devices, evidenced by Pearson correlation coefficients (r) with the following
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qualitative interpretation: negligible (< 0.1), small (0.1–0.29), moderate (0.3–0.49), high (0.5–0.69),
very high (0.7–0.89) or almost perfect (≥ 0.9) [18]. Analysis 2: Level of similarity in group estimates,
evidenced by non-significant differences in the peak acceleration means assessed by a dependent
t-test. Analysis 3: Absence of measurement bias (level of agreement between devices) evidenced by
Bland–Altman plots, including the 95% confidence interval for upper and lower limits.
The level of alpha for all analyses was set at p < 0.05 with analyses performed for each exercise
test (CMJ and treadmill bouts) and for each measured location (hip and wrist). Statistical analysis
was performed using the Jamovi software (version 1.0.7.0 The Jamovi Project 2019, retrieved from
https://www.jamovi.org).
3. Results
The demographic and clinical characteristics of the eighteen female participants are presented in
Table 1.
Table 1. Participants’ descriptive statistics.
Mean SD
Age (years) 44.2 4.8
Body mass (kg) 62.7 9.5
Stature (cm) 165.0 7.1
3.1. Analysis 1: Association between Measurements from Both Devices
Firstly, to ascertain if the output from Muvone® was associated with that of the GT3X+,
Pearson correlation coefficients were calculated. Peak accelerations measured by Muvone® and
GT3X+ were positively and significantly correlated for all exercise tests (CMJ and treadmill bouts at all
velocities). For the CMJ a very high correlation at the wrist (r = 0.894, p < 0.001) and an almost perfect
correlation at the hip (r = 0.935, p < 0.001) were found (Table 2). For the treadmill bouts, high to almost
perfect correlations at the hip (r = 0.607–0.902, p < 0.001) and almost perfect correlations at the wrist
(r > 0.9, p < 0.001) were obtained (Table 2).
Table 2. Correlation analyses between the Muvone® and GT3X+.
Accelerometers
Location Test Pearson’s r 95% CI
1 Pearson’s r
(>3.9 g) 95% CI
1
Wrist
CMJ2 0.894 0.839–0.931 0.777 0.633–0.869
4.8 km·h−1 0.967 0.964–0.969 0.786 0.680–0.859
6.4 km·h−1 0.975 0.972–0.833 0.878 0.857–0.896
9.7 km·h−1 0.911 0.904–0.918 0.859 0.847–0.870
12 km·h−1 0.901 0.888–0.913 0.868 0.850–0.884
Hip
CMJ2 0.935 0.886–0.963 0.905 0.806–0.955
4.8 km·h−1 0.818 0.802–0.833 0.434 −0.390–0.872
6.4 km·h−1 0.902 0.892–0.910 0.413 0.219–0.522
9.7 km·h−1 0.655 0.628–0.680 0.330 0.274–0.384
12 km·h−1 0.607 0.553–0.656 0.446 0.370–0.516
1 CI: Confidence interval. 2 CMJ: Countermovement jump.
Pearson correlation coefficients were also calculated selecting only measurements above 3.9 g.
This acceleration value has been previously described as a threshold for osteogenic physical activity [11].
For the CMJ a very high correlation at the wrist (r = 0.777, p < 0.001) and an almost perfect correlation
at the hip (r = 0.905, p < 0.001) were found (Table 2). For the treadmill bouts, moderate correlations
were obtained at the hip (r = 0.330–0.446, p < 0.001) and very high correlations at the wrist (r > 0.7,
p < 0.001) (Table 2).
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3.2. Analysis 2: Level of Similarity in Group Estimates
The descriptive statistics of peak acceleration measured at each exercise test, device and
accelerometer location are presented in Table 3.
Table 3. The mean, median, standard deviation and standard error for peak accelerations.
Test Device Location Mean Median SD2 SE3
CMJ1 ActiGraph Hip 4.32 g 4.14 g 1.08 g 0.16 g
CMJ1 Muvone Hip 4.46 g 4.46 g 1.23 g 0.18 g
CMJ1 ActiGraph Wrist 4.21 g 4.17 g 0.79 g 0.09 g
CMJ1 Muvone Wrist 4.20 g 4.24 g 0.92 g 0.10 g
4.8 km/h ActiGraph Hip 1.79 g 1.75 g 0.26 g 0.07 g
4.8 km/h Muvone Hip 1.75 g 1.67 g 0.34 g 0.09 g
4.8 km/h ActiGraph Wrist 1.89 g 1.70 g 0.65 g 0.15 g
4.8 km/h Muvone Wrist 1.82 g 1.63 g 0.63 g 0.15 g
6.4 km/h ActiGraph Hip 2.64 g 2.39 g 0.99 g 0.27 g
6.4 km/h Muvone Hip 2.67 g 2.31 g 1.11 g 0.30 g
6.4 km/h ActiGraph Wrist 3.06 g 2.27 g 1.56 g 0.37 g
6.4 km/h Muvone Wrist 2.89 g 2.10 g 1.47 g 0.35 g
9.7 km/h ActiGraph Hip 4.23 g 3.85 g 0.87 g 0.23 g
9.7 km/h Muvone Hip 4.45 g 4.40 g 0.93 g 0.24 g
9.7 km/h ActiGraph Wrist 5.41 g 5.38 g 1.08 g 0.25 g
9.7 km/h Muvone Wrist 5.10 g 5.08 g 0.99 g 0.23 g
12 km/h ActiGraph Hip 4.80 g 4.45 g 0.85 g 0.38 g
12 km/h Muvone Hip 5.02 g 5.06 g 0.77 g 0.34 g
12 km/h ActiGraph Wrist 6.73 g 6.41 g 1.43 g 0.54 g
12 km/h Muvone Wrist 6.40 g 6.04 g 1.26 g 0.48 g
1 CMJ: Countermovement jump. 2 SD: Standard deviation. 3 SE: Standard error.
To assess if the outputs from the devices yielded similar group estimates, the differences between
peak acceleration means measured by Muvone® and GT3X+ for each participant were assessed using
dependent t-tests. Non-significant differences were found for all tests and accelerometer locations
(Table 4).
Table 4. T-tests results.
Accelerometers
Location Test
Difference between Peak
Acceleration Means (GT3X -
Muvone)
95% CI1
Wrist
CMJ2 0.006 g (p = 0.96) −0.260–0.272
4.8 Km/h 0.073 g (p = 0.73) −0.360–0.506
6.4 Km/h 0.165 g (p = 0.75) −0.864–1.195
9.7 Km/h 0.311 g (p = 0.37) −0.389–1.011
12 Km/h 0.326 g (p = 0.66) −1.245–1.896
Hip
CMJ2 −0.143 g (p = 0.55) −0.613–0.327
4.8 Km/h 0.048 g (p = 0.68) −0.189–0.285
6.4 Km/h −0.033 g (p = 0.93) −0.849–0.783
9.7 Km/h −0.215 g (p = 0.52) −0.891–0.461
12 Km/h −0.215 g (p = 0.69) −1.398–0.968
1 CI: Confidence interval. 2 CMJ: Countermovement jump.
The comparison between peak acceleration means measured by GT3X+ and Muvone® at hip and
wrist during the CMJ test can be observed in Figure 2. Non-significant differences were found between
the two activity monitors as evidenced by dependent t-tests.
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3.3. Analysis 3: Level of Agreement between Devices
Finally, the level of agreement between devices was assessed using Bland–Altman analysis.
The mean bias for every test and location, as well as the upper and lower limits of agreement (95%
limits) can be found in Table 5.
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Table 5. Bland–Altman analysis.
Accelerometer
Location Test
Mean Bias (GT3X -
Muvone)
Lower Limit of
Agreement
Upper Limit of
Agreement
Wrist
CMJ1 0.006 g (0.88%) −0.804 g 0.816 g
4.8 km·h−1 0.072 g (3.79%) −0.251 g 0.395 g
6.4 km·h−1 0.163 g (5.27%) −0.558 g 0.884 g
9.7 km·h−1 0.313 g (5.77%) −0.845 g 1.471 g
12 km·h−1 0.333 g (4.97%) −1.172 g 1.839 g
Hip
CMJ1 −0.143 g (−2.52%) −1.011 g 0.725 g
4.8 km·h−1 0.049 g (4.33%) −0.526 g 0.623 g
6.4 km·h−1 −0.032 g (−1.26%) −1.026 g 0.962 g
9.7 km·h−1 −0.178 g (−1.68%) −2.349 g 1.994 g
12 km·h−1 −0.218 g (−2.88%) −2.341 g 1.906 g
1 CMJ: Countermovement jump.
In all tests and locations the absolute mean bias was below 0.35 g and relative mean bias was
below 6%. Therefore, Bland–Altman plots showed high agreement between the peak accelerations
measured by GT3X+ and Muvone® at the hip and wrist for both CMJ and treadmill bouts (4.8, 6.4,
9.7 and 12 km·h−1) (Figure 4).
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for the lower limit of agreement.
4. Discussion
The aim of this study was to determine the validity of Muvone® , a wearable accelerometer-
based activity monitor, in order to assess its suitability for the implementation of population-wide 
osteoporosis prevention programs. Its validity has been tested against ActiGraph GT3X+, as 
Figure 4. Bland–Altman plots. High agreement between the devices was sh wn for every test and
location: (a) Test: CMJ. Accelerom t s location: Wrist. (b) Test: CMJ. Acc lerometers location:
Hip. (c) T st: Treadmill 4.8 km·h−1. Acc lerometers location: Wrist. (d) Test: Treadmill 4.8 km·h−1.
Accelerometers location: Hip. (e) Te t: Treadmill 6.4 km·h−1. Accelerometers location: Wrist. (f) Te t:
Treadmill 6.4 km·h−1. Accelero eters location: Hip. (g) Test: Treadmill 9.7 km·h−1. Acc lerometers
location: Wrist. (h) Test: Treadmill 9 7 km·h−1. Accelerometers location: Hip. (i) Test: Treadmill 12
km·h−1. Accelerometers lo ation: Wrist. (j) Test: Tr admill 12 km·h−1. Acc lerometers location: Hip.
The green band d picts the 95% confidence interval for the upper limit of agreement, the blue band
depicts th 95% c nfidence i erval for the mean bias, and the red band depicts the 95% confidence
interval for the lower limit of agreement.
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4. Discussion
The aim of this study was to determine the validity of Muvone®, a wearable accelerometer-based
activity monitor, in order to assess its suitability for the implementation of population-wide osteoporosis
prevention programs. Its validity has been tested against ActiGraph GT3X+, as ActiGraph activity
monitors are widely used in physical activity research [14] and their reliability to measure acceleration
accurately has been previously reported [15]. Measurements from both devices were positively and
significantly correlated for all exercise tests (CMJ and treadmill bouts at all velocities), showing a very
high to almost perfect correlation. Pearson correlation coefficients were also calculated selecting only
measurements above 3.9 g, as this acceleration value has been previously described as a threshold
for osteogenic physical activity [11]. Bone adaptations display a dose- and intensity-dependent
relationship with mechanical loading, and these authors found positive BMD changes at the proximal
femur with an exercise dose of at least of 60 impacts per day exceeding the acceleration level of 3.9 g.
Therefore, accelerometer-based activity monitors should provide accurate measurements above this
level in order to be considered for the implementation of osteoporosis prevention programs. In the
current study, for measurements over 3.9 g moderate to very high correlations between Muvone® and
GT3X+ were found for all tests (CMJ and treadmill bouts) and both accelerometer locations (hip and
wrist) (Table 2).
To assess the level of similarity in group estimates from both devices, the differences between
outputs were assessed using t-tests (p < 0.05), and non-significant differences were found for all tests
and locations (Table 4).
Finally, absence of measurement bias (level of agreement between devices) was evidenced by
Bland–Altman plots (Table 5). Relative mean bias was below 6%, which translates into an absolute bias
below 0.35 g for all exercise tests and accelerometer locations, an error value reasonably acceptable in
an osteoporosis prevention exercise program.
In people affected by osteoporosis, the threshold between an effective stimulus for positive bone
adaptations and a harmful stimulus for bone integrity could be reduced. Therefore, in order to ensure
the effectiveness and safety of an osteoporosis prevention exercise program, accurate monitoring of
mechanical loading is necessary. Traditionally, the effect of physical activity on bone health is studied
by employing force platforms to measure ground reaction force. These devices are mostly limited to
laboratory environments [10]. Wearable accelerometer-based activity monitors provide the opportunity
for a wider population to participate in osteoporosis prevention programs.
A limitation in this study was the array of physical activities tested. The exercise protocol included
CMJ and treadmill bouts at different speeds. During normal daily life, many other activities take
place that imply accelerations that would need further analysis. Besides, many activities involve
arm movement that is dissociated from lower body movement (e.g., sweeping, carrying bags, etc.).
Therefore, when assessing physical activity that may be beneficial for bone health, the relevant
accelerometer location must be considered. Moreover, because this was a non-experimental study,
causal associations cannot be made and thus we are not able to determine if an accurate quantification
of the mechanical loading during physical activities can incur bone mineral density changes in
premenopausal women. Finally, and although our sample was relatively homogeneous in age,
it was small and thus our results might not be generalizable to other age groups. Despite these
limitations, our data support the validity of both wrist-worn and hip-worn Muvone® accelerometers
in premenopausal women.
5. Conclusions
In conclusion, the validity of Muvone® to quantify acceleration has been tested at both the
wrist and hip, and also with measurements above 3.9 g, an acceleration value previously described
as a threshold for osteogenic physical activity [11]. Therefore, Muvone® could be used to assess
mechanical loading in physical activities for the implementation of population-wide osteoporosis
prevention programs.
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